Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rLZ-8 in treating thrombopenia and preparation thereof

A technology for thrombocytopenia and pharmaceutical preparations, which is applied in the application of rLZ-8 in the treatment of thrombocytopenia and its preparations, can solve the problems affecting the persuasiveness of the curative effect, curative effect evaluation stays in effective, ineffective, and different curative effect standards

Inactive Publication Date: 2009-12-30
张喜田
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are also reports on the application of traditional Chinese medicine in the treatment of thrombocytopenia. Among them, single Chinese medicine and compound preparations mainly include ginseng, angelica, psoralen, rehmannia glutinosa, Atractylodes macrocephala, astragalus, donkey-hide gelatin, and Acanthopanax. The hematopoietic and immune function suppression caused by it has a good regulatory effect, but the current curative effect evaluation only stays at the level of effective and ineffective, and because of the different curative effect standards in different places, many reports do not have a control group, and the length of treatment varies greatly. persuasion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rLZ-8 in treating thrombopenia and preparation thereof
  • Application of rLZ-8 in treating thrombopenia and preparation thereof
  • Application of rLZ-8 in treating thrombopenia and preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1. The pharmacodynamics test of rLZ-8 preventing canine thrombocytopenia caused by cyclophosphamide

[0012] 1. Drug preparation:

[0013] Test drug: Recombinant Ganoderma lucidum immunomodulatory protein (rLZ-8) was prepared in 3.85 μg·kg sterile saline -1 , 1.925 μg kg -1 Dosage group, 1ml / piece.

[0014] Positive control drug: Thrombopoietin (THPO), produced by Shenyang Sansheng Pharmaceutical Co., Ltd., 20 μg kg -1 / d, 1ml / piece.

[0015] Chemotherapy drug: Cyclophosphamide (Cy), produced by Jiangsu Hengrui Pharmaceutical Co., Ltd., production batch number 08112121; 200mg / bottle. Accurately weigh 7mg·kg with an electronic scale -1 / Only.

[0016] Platelet diluent: urea: 1.3g, sodium citrate: 0.5g, formaldehyde: 0.1ml, add distilled water to 100ml and mix, filter for later use.

[0017] 2. Experimental method:

[0018] The experimental animals were divided into 5 groups, namely normal control group, model group (CP), positive drug control group and ex...

Embodiment 2

[0026] Example 2. The pharmacodynamics test of rLZ-8 in the treatment of canine thrombocytopenia caused by cyclophosphamide

[0027] 1. Drug preparation:

[0028] Test drug: Recombinant Ganoderma lucidum immunomodulatory protein (rLZ-8) was prepared in 3.85 μg·kg sterile saline -1 , 1.925 μg kg -1 Dosage group, 1ml / piece.

[0029] Positive control drug: Thrombopoietin (THPO), produced by Shenyang Sansheng Pharmaceutical Co., Ltd., 20 μg kg -1 / d, 1ml / piece.

[0030] Chemotherapy drug: Cyclophosphamide (Cy), produced by Jiangsu Hengrui Pharmaceutical Co., Ltd., production batch number 08112121; 200mg / bottle. Accurately weigh 7mg·kg with an electronic scale -1 / Only.

[0031] Platelet diluent: urea: 1.3g, sodium citrate: 0.5g, formaldehyde: 0.1ml, add distilled water to 100ml and mix, filter for later use.

[0032] 2. Experimental method:

[0033] The experimental animals were divided into 5 groups, namely normal control group, model group (CP), positive drug control gro...

Embodiment 3

[0041] Example 3. The pharmacodynamics test of rLZ-8 preventing the mouse thrombocytopenia caused by cyclophosphamide

[0042] 1. Drug preparation:

[0043] Test drug: Recombinant Ganoderma lucidum immunomodulatory protein (rLZ-8) was prepared with sterile water for injection to 19.25 μg kg -1 , 9.625 μg kg -1 Dosage group, 0.2ml / piece.

[0044] Positive control drug: Thrombopoietin (THPO), produced by Shenyang Sansheng Pharmaceutical Co., Ltd., 770 μg kg -1 / d, 0.2ml / piece.

[0045] Chemotherapy drug: Cyclophosphamide (Cy), produced by Jiangsu Hengrui Pharmaceutical Co., Ltd., production batch number 08112121; 200mg / bottle. Prepare 100mg·kg with sterile water for injection -1 , 0.2ml / piece.

[0046] Platelet diluent: urea: 1.3g, sodium citrate: 0.5g, formaldehyde: 0.1ml, add distilled water to 100ml and mix, filter for later use.

[0047] 2. Experimental method:

[0048] Experimental animals were divided into 5 groups, 10 mice in each group, half male and half male. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a novel application of a recombinant ganoderma lucidum immunological regulation protein (rLZ-8) in treating thrombopenia. In the experiments of preventing and treating the thrombopenia of rats and dogs caused by cyclophosphamide, the rLZ-8 prepared from physiological saline carries out administration on an experimental animal model with lower thrombocytes, THPO and IL-6 are used as positive medicines, continuous administration is carried out, the number of the thrombocytes in blood is detected, the changes of the number of the thrombocytes before and after therapy are contrasted, and the medicine effect is analyzed. Compared with a model group, the rLZ-8 medicine group already obviously stimulates the thrombocyte proliferation of rats, Guinea pigs and dogs in the initial period (the 3rd day to the 5th day) of the administration, the difference is very obvious, the thrombocytes are recovered to a normal level in the middle period (the 7th day to the 10th day) of the administration, and the invention also obtains a very good effect in treating the thrombopenia of a Guinea pig experimental animal model caused by injecting anti-thrombocyte serum.

Description

technical field [0001] The invention relates to a therapeutic application of recombinant Ganoderma lucidum immunoregulatory protein (rLZ-8) to thrombocytopenia. Background technique [0002] In 1989, an immunoregulatory protein was isolated for the first time from the mycelia extract of red Ganoderma lucidum by Japan Kino et al. , and its gene sequence, amino acid sequence and immunophysiological activity were determined. Protein sequencing revealed that LZ-8 consists of 110 amino acid residues and is acetylated at the amino terminus. The molecular weight is 12.4kD, and the isoelectric point is 4.4. [0003] One of the inventors has disclosed in another patent application the crystallographic structure of the recombinant Ganoderma lucidum immunoregulatory protein. FNIII domain, the N-terminal domain consists of an α-helix (sequence 2-SDTA-LIFRLAWDVK-15, composed of 14 amino acids) and β-strand (sequence 16-KLSFD-20, composed of 5 amino acids), in which The Ser residue on...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P7/00
CPCA61K38/168A61P7/00
Inventor 孙非梁重阳张喜田
Owner 张喜田
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com